Lyell Immunopharma, Inc.

LYEL Healthcare Biotechnology

Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024.

Revenue
−80.0%
EPS
+12.7%
Free cash flow
−21.8%

Quarter to September 2026, against a year earlier

14.82 0.18 −1.20%
Market cap
$367.6M
P/E
0.0×
Fwd P/E
−1.5×
Dividend yield
—
F-score
2/9
Altman Z
−5.10
Beneish M
n/a
Dividend safety
n/a
Sep '26 From the 10-Q filed 4 Nov Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
2 2 2 2

+8 more TTM periods

ROE
(97.79%) (93.28%) (80.76%) (86.98%)
ROA
(74.85%) (71.34%) (63.15%) (66.06%)
ROIC
(1,070.83%) (539.53%) (815.53%) (17,146.38%)
Return on Tangible Assets
(151.45%) (121.69%) (93.66%) (111.43%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(5.70) (7.48) (8.01) (11.22)
Free Cash Flow
(139.25) (174.87) (175.33) (191.71)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 4 Nov 2026